狄潘潘,贾淑云,王杰,王志远,李帅,岳云月.帕博利珠单抗致免疫相关性不良反应文献回顾性分析[J].中国药事,2021,35(10):1192-1198 |
帕博利珠单抗致免疫相关性不良反应文献回顾性分析 |
Retrospective Analysis to Literature of Immune-related Adverse Drug Reactions of Pabolizumab |
|
DOI:10.16153/j.1002-7777.2021.10.016 |
中文关键词: 帕博利珠单抗 不良反应 文献分析 临床表现 |
英文关键词: pabolizumab adverse reactions literature analysis clinical manifestations |
基金项目: |
|
摘要点击次数: 1119 |
全文下载次数: 9 |
中文摘要: |
目的:分析帕博利珠单抗药品不良反应(Adverse Drug Reactions,ADR)的发生情况和临床特点,为临床合理用药提供参考。方法:检索中国知网、万方、维普、PubMed、Springer及Wiley中关于帕博利珠单抗的ADR个案报道,对其进行统计和分析。结果:帕博利珠单抗致ADR个案报道共41篇53例。 患者的年龄主要为51~70岁(54.71%)。ADR多发生在用药3个月后(47.37%),以皮肤系统(47.37%) 损害多见。ADR主要表现为大疱性类天疱疮(8例次)和视力下降(5例次)等。结论:在临床使用帕博利珠单抗时应注意监测和防治其ADR,避免严重的ADR发生。 |
英文摘要: |
To analyze the occurrence and clinical characteristics of Adverse Drug Reactions (ADR) of pabolizumab, and provide references for the rational use of drugs in clinical practice. Methods: Literature related to adverse reaction case reports of pabolizumab in CNKI database, Wanfang database, VIP database, PubMed, Springer and Wiley were searched for statistics and analysis. Results: There were 41 reports and 53 cases of ADR induced by Pabolizumab in the literature. The age of the patients was mainly from 51 to 70 years old (54.71%). ADR mostly occurred after 3 months of medication (47.37%), and damage to the skin system (47.37%) was more common. The main manifestaftions of ADR were bullous pemphigoid (8 cases) and decreased vision (5 cases). Conclusion: In clinical use of pabolizumab, attentions should be paid to the monitoring and prevention of its ADR so as to avoid the occurrence of severe ADR. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|